Why the study?
Pre-clinical studies of mitoprotective strategies have targeted mitochondrial functions to limit damage after acute MI, but none have successfully translated to the clinic.
This ESC scientific statement provides a consensus opinion on the obstacles and future strategies for translating mitochondrial-targeted therapies into cardioprotective treatments for ischemic heart disease and heart failure.
Answers are grounded in this paper and cite their sources.
No mitochondrial therapy should enter clinical use for IHD or HF yet; extends pre-clinical data by delineating timing, bioavailability, and comorbidity barriers for targeted research.
Acute myocardial infarction (MI) remains a major cause of death and disability worldwide. No adjuvant treatment has yet been fully validated in patients to limit the progression from the initial tissue damage due to acute MI, to the development of heart failure. However, mitochondria have long been demonstrated to be a key target for cardioprotective strategies to reduce cell death that leads to left ventricular dysfunction and ultimately heart failure. While pre-clinical studies have investigated several mitoprotective strategies targeting different mitochondrial functions, such as oxidative stress or permeability transition pore opening, none have shown successful clinical translation so far. In this European Society of Cardiology scientific statement, we present recent research advances in the understanding of the mitochondrial alterations occurring in MI and in the discovery of key components of mitochondrial structure and function in order to improve drug development. We discuss the reasons for the failure of clinical translation and the remaining obstacles that need to be addressed, including timing of drug administration, tissue bioavailability and efficient mitochondrial targeting, together with the mitochondrial impact derived from risk factors, comorbidities and comedications. Taken together, this scientific statement aims to provides a consensus opinion from clinicians and basic scientists to translate some of the most promising mitoprotective targets into the clinical setting to protect against MI and heart failure.
No takes yet. Share an insight, caveat, or question.
Paillard et al. (2025) conducted a review in Ischemic Heart Disease and Heart Failure. Mitochondria-targeted therapies was evaluated.
Synapse has enriched 10 related papers. Consider them for comparative context: